Infrequent Navenibart Dosing Reduces HAE Attacks in Early Trial Findings

Imagine waking up one morning in downtown Austin, your hands swollen like balloons, your throat tightening with every breath—another hereditary angioedema (HAE) attack striking without warning. For the roughly 1 in 50,000 Americans living with this rare genetic disorder, these episodes aren’t just painful; they’re a constant threat lurking beneath the surface of daily life. But what if a single injection could keep those attacks at bay for months, not days? That’s the promise emerging from early clinical trials of navenibart, an experimental therapy that could reshape how HAE is managed—and it’s news that hits especially close to home for Central Texas families already navigating the challenges of this unpredictable condition.

Here’s the breakthrough: In a Phase 1b/2 trial known as ALPHA-STAR, patients receiving navenibart experienced a significant delay in the time to their first HAE attack compared to placebo. The therapy, developed by Astria Therapeutics, is a long-acting monoclonal antibody designed to inhibit plasma kallikrein—a key protein in the biochemical cascade that triggers swelling episodes. Unlike current prophylactic treatments that require frequent dosing (some as often as every few days), navenibart’s early data suggests it could offer protection with injections spaced months apart. For a community like Austin, where access to specialized care can mean a two-hour drive to the nearest HAE clinic, the implications are profound.

The Science Behind the Headlines: Why Navenibart Stands Out

HAE isn’t just another allergy—it’s a genetic defect in the SERPING1 gene (for Type I and II HAE) or the FXII gene (for Type III), leading to uncontrolled production of bradykinin, a peptide that causes blood vessels to leak fluid into surrounding tissues. The result? Recurrent swelling in the face, limbs, gastrointestinal tract, and—most dangerously—the airway. Current treatments fall into two categories: on-demand therapies (like icatibant or ecallantide) to stop attacks in progress, and prophylactic options (such as lanadelumab or C1 inhibitors) to prevent them. But here’s the catch: most prophylactics require injections every 2 to 4 weeks, and some patients still experience breakthrough attacks.

Navenibart’s early trial data, published in The Journal of Allergy and Clinical Immunology, offers a glimpse of a different future. In the ALPHA-STAR study, patients receiving a single dose of navenibart went a median of 92 days before their first HAE attack, compared to just 35 days for those on placebo. Even more striking, some participants remained attack-free for the entire 24-week observation period. These aren’t just numbers on a page—they represent the potential for fewer emergency room visits, fewer missed days of work or school, and, perhaps most importantly, fewer moments of sheer terror when swelling begins in the throat.

Dr. Marc Riedl, a leading HAE researcher at the US Hereditary Angioedema Association (HAEA) and a consultant on the trial, noted in the study’s discussion that the therapy’s extended half-life could “dramatically reduce the treatment burden for patients.” For Austinites, where traffic and distance already complicate access to care, a therapy that requires fewer clinic visits could be life-changing. Imagine a parent of a child with HAE no longer having to choose between a family vacation and a scheduled infusion, or a young professional not having to explain yet another absence to their employer.

Why Austin? The Local Ripple Effects of a Rare Disease Breakthrough

Austin’s reputation as a hub for biotech and innovation isn’t just about startups and tech giants—it’s as well home to a growing network of rare disease advocates, researchers, and specialized clinics. The Dell Medical School at The University of Texas at Austin has been expanding its focus on genetic disorders, and the city’s central location makes it a natural gathering point for patients from across Texas and the Southwest. But despite these resources, HAE remains underdiagnosed and often misunderstood, even among primary care providers.

Take, for example, the story of Sarah M. (name changed for privacy), a 32-year-old Austin resident who spent years misdiagnosed with allergies or anxiety before finally receiving an HAE diagnosis at the Texas Allergy, Asthma & Immunology Society (TAAIS) clinic. “I’d head to the ER with swelling, and they’d send me home with antihistamines,” she recalls. “It wasn’t until I saw a specialist who recognized the pattern that I got answers.” Sarah’s experience isn’t unique—studies suggest the average HAE patient sees five doctors over eight years before receiving a correct diagnosis. For a city like Austin, where the population is booming and healthcare resources are stretched thin, a therapy like navenibart could ease some of that diagnostic and treatment burden.

But the impact goes beyond individual patients. Austin’s economy thrives on its creative and tech workforce, where unpredictable health issues can derail careers. The Austin Chamber of Commerce has long emphasized the importance of healthcare innovation in attracting and retaining talent. If navenibart progresses through Phase 3 trials (the ORBIT-EXPANSE study is currently enrolling patients), it could position Austin as a leader in rare disease care—drawing more clinical trials, investment, and specialized providers to the region. It’s a ripple effect that starts with a single injection but could reshape the city’s healthcare landscape.

The Road Ahead: What’s Next for Navenibart—and for Austin’s HAE Community

Even as the early data is promising, it’s important to temper excitement with caution. The ALPHA-STAR trial was small (just 36 patients), and larger studies are needed to confirm navenibart’s safety and efficacy. The Phase 3 ORBIT-EXPANSE trial, which began enrolling patients in late 2025, will include hundreds of participants worldwide—including sites in Texas. For Austinites interested in participating, the Clinical Trials of Texas, Inc. (a local research organization) is one of the enrolling centers, offering a chance to be at the forefront of this potential breakthrough.

But even as the science progresses, the local HAE community isn’t waiting. The HAEA’s Austin Support Group, which meets monthly at the Seton Medical Center, has seen growing attendance as awareness of the condition spreads. “We’re seeing more newly diagnosed patients every month,” says group leader Linda Carter, a longtime HAE advocate. “The challenge is making sure they know about the resources available—and that includes clinical trials like this one.”

For those who’ve spent years managing HAE with older therapies, the prospect of a long-acting prophylactic is more than just a medical advancement—it’s a potential return to normalcy. “I’ve had patients tell me they haven’t taken a vacation in years because they’re afraid of having an attack,” says Dr. Emily Chen, an allergist-immunologist at Ascension Seton. “If navenibart delivers on its promise, it could give them back something priceless: peace of mind.”

Beyond the Lab: How Austin’s HAE Community Can Prepare

So what does this mean for Austinites living with HAE—or those who suspect they might have it? First, it’s a reminder that rare diseases are often hiding in plain sight. If you or a loved one experiences unexplained swelling, especially if it’s accompanied by abdominal pain or throat tightness, seek out a specialist. The TAAIS maintains a directory of allergists-immunologists in the region, and the HAEA offers free diagnostic testing for those who qualify.

Second, stay informed about clinical trials. The ORBIT-EXPANSE study is actively recruiting, and participating could provide access to cutting-edge care while advancing research. For those who prefer to wait for FDA approval, it’s worth noting that navenibart’s path could be accelerated under the FDA’s Breakthrough Therapy designation, which is granted to drugs that present substantial improvement over existing treatments. If that happens, the therapy could be available as early as 2028.

Finally, connect with the local HAE community. The HAEA Austin Support Group meets on the third Thursday of every month at Seton Medical Center, offering a space to share experiences, learn about new treatments, and find solidarity. In a city as vibrant and fast-paced as Austin, it’s straightforward to feel alone in a rare disease diagnosis—but the truth is, there’s a growing network of patients, providers, and advocates ready to help.

Given My Background in Rare Disease Advocacy, Here’s Who You Should Know in Austin

If you or someone you love is navigating HAE—or any rare genetic disorder—in Central Texas, finding the right specialists can feel overwhelming. Based on my years covering rare disease breakthroughs and connecting patients with resources, here are the three types of local professionals who can build a difference in your care journey:

1. Allergist-Immunologists with Rare Disease Expertise

Why they matter: HAE is often misdiagnosed as an allergy, so you need a specialist who understands the nuances of bradykinin-mediated swelling. Look for providers affiliated with the TAAIS or who have published research on HAE.

What to ask:

• “How many HAE patients do you currently treat?” (Aim for at least 10-15.)
• “Are you involved in any clinical trials for new HAE therapies?” (This signals they’re up-to-date on emerging treatments.)
• “Do you work with a multidisciplinary team, including genetic counselors?” (HAE management often requires a collaborative approach.)

Where to find them: The Dell Medical School and Ascension Seton both have immunology departments with rare disease expertise. The HAEA’s physician directory is also a great starting point.

2. Genetic Counselors Specializing in Hereditary Disorders

Why they matter: HAE is genetic, which means family members may also be at risk. A genetic counselor can help interpret test results, assess inheritance patterns, and guide decisions about testing for relatives.

What to ask:

• “What percentage of your practice focuses on hereditary angioedema or related disorders?” (You desire someone with deep experience in this specific condition.)
• “Do you offer telehealth consultations for family members who live out of state?” (What we have is crucial for coordinating care across distances.)
• “How do you approach genetic testing for children?” (HAE can present in childhood, so pediatric expertise is valuable.)

Where to find them: The Texas Department of State Health Services maintains a list of certified genetic counselors, and the National Society of Genetic Counselors offers a searchable database. Locally, the Dell Children’s Medical Center has a dedicated genetics team.

3. Patient Advocacy Navigators

Why they matter: Rare diseases come with a maze of insurance hurdles, prior authorization battles, and financial assistance programs. A patient advocate can help you access treatments, appeal denials, and find copay assistance.

What to ask:

• “What’s your success rate in securing coverage for HAE-specific therapies?” (Look for advocates with a track record in rare diseases.)
• “Do you have experience with the HAEA’s Patient Assistance Program or other financial aid resources?” (This can significantly reduce out-of-pocket costs.)
• “Can you help coordinate care between multiple specialists?” (HAE often requires input from allergists, gastroenterologists, and ENTs.)

Where to find them: The HAEA offers free patient advocacy services, and organizations like the Patient Advocate Foundation provide case management for complex conditions. Locally, the Central Texas Health Alliance connects patients with navigators who understand the region’s healthcare landscape.

Navigating a rare disease like HAE can feel isolating, but Austin’s growing network of specialists and advocates is here to help. Whether you’re exploring clinical trials, seeking a second opinion, or just looking for someone who understands, these professionals can guide you through the challenges—and the hope—of living with a chronic condition in a city that’s rapidly becoming a hub for rare disease care.

Ready to find trusted professionals? Browse our complete directory of top-rated rare disease experts in the Austin area today.